Type 2 diabetes was associated with 70% higher risk of mortality among patients with ischemic heart failure, a study found. Another study revealed a correlation between type 2 diabetes and a 39% higher death risk among patients with heart failure and preserved left ventricular ejection fraction. The results were reported at the European Association for the Study of Diabetes meeting.
The use of homeostatic model assessment of insulin resistance with values ranging from 1.0 to 2.0 was associated with increased odds of heart failure in patients compared with HOMA-IR values above 2.5, a study indicated. The results were published in the Journal of the American College of Cardiology: Heart Failure.
Data from the U.S. Collaborative Perinatal Project that included more than 28,800 term babies showed those with maximum serum bilirubin levels greater than 15 mg/dL had a 61% higher risk of having childhood asthma than those with levels of 3 mg/dL or less. Both the maximum total serum bilirubin levels as well as levels at 48 hours postpartum were substantially correlated with asthma prevalence, researchers from China reported in the American Journal of Epidemiology.
A Canadian study found that giving ICU patients the amino acid glutamine in intravenous fluids raised their risk of death by 30%, and that replacing antioxidants did not reduce the likelihood of death or organ failure. The study, published in the New England Journal of Medicine, included 1,223 patients with multi-organ failure in 40 ICUs in the U.S., Canada and Europe.
Boston Scientific has received FDA approval for its three defibrillators, called Incepta, Punctua and Energen, which are used to treat sudden cardiac death and heart failure. The devices feature the company's DF4 universal connector tool to work with thinner and smaller platforms, and its Latitude Heart Failure Management tool to allow for remote surveillance.